دوره 29، شماره 155: هفته سوم آبان ماه 1390:1381-1388

بررسی ارتباط بین سطح سرمی ‌مارکرهای توموری با شدت فیبروز کبد در بیماران مبتلا به هپاتیت مزمن و سیروز

مریم حیدرپور, حمید توکلی, داوود شفیعی, نوید کلینی, اکبر ارجمندپور

چکیده


مقدمه: مطالعات متعدد در جوامع مختلف ارتباط بین سطح سرمی بعضی مارکرهای بیوشیمیایی مانند CA125، CA15-3، a.Fetoprotein و CA19-9 را با شدت فیبروز کبدی نشان داده‌اند. مطالعه‌ی حاضر جهت بررسی این ارتباط در بیماران مبتلا به هپاتیت مزمن انجام گرفت.

روش‌ها: در این مطالعه‌ی توصیفی- تحلیلی در مجموع 30 بیمار در شهرستان اصفهان بررسی شدند. ابتدا اطلاعات دموگرافیک، قد و وزن کلیه‌ی بیماران ثبت و سپس میزان پلاکت، AST، ALT، CA 19-9، CA15-3، 125CA- و آلفا فیتوپروتئین سرم آن‌ها اندازه‌گیری شد. آن گاه، بیوپسی کبد انجام و شدت فیبروز با استفاده از روش طبقه‌بندی شاخص فعالیت بافتی (Histological activity index یا HAI) تعیین شد. داده‌ها توسط آزمون‌های Multivariant logistic regression، ضریب همبستگی Spearman و Generalized linear regression تجزیه و تحلیل شد.

یافته‌ها: سطح سرمی CA15-3، CA19-9 و آلفا فیتوپروتئین با شدت فیبروز کبد ارتباط معنی‌دار داشت. این ارتباط بین سطح سرمی CA125 و فیبروز کبد ‌یافت نشد (079/0 = P).

نتیجه‌گیری: یافته‌های ما ارتباط بین CA15-3،  CA19-9و آلفا فیتوپروتئین را با فیبروز کبدی نشان داد. به علت حجم نمونه‌ی کم نمی‌توان استفاده از تومور مارکرهای فوق را به عنوان راهی برای تشخیص مرحله‌ی فیبروز کبدی معرفی کرد اما می‌توان بیان کرد که بالا بودن سطح سرمی تومور مارکرها به طور قطع نشانه‌ی بیماری بدخیم در این گروه بیماران نیست.


واژگان کلیدی


CA15-3؛ CA 125؛ CA19-9؛ آلفافیتوپروتئین؛ فیبروز کبد؛ هپاتیت مزمن

تمام متن:

PDF

مراجع


ANCAHRD Hepatitis C Sub-Committee. Estimates and Projections of Hepatitis C Virus Epidemic in Australia. Sydney: National Centre in HIV, Epidemiology and Clinical Research; 2002.

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41-52.

Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362(9401): 2095-100.

Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8): 556-62.

Gordon A, Bailey MJ, Gibson PR, Roberts SK. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. J Gastroenterol Hepatol 2005; 20(6): 825-32.

Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S35-S46.

Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(3 Suppl 1): 34S-8S.

Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J 2008; 31(1): 16-25.

Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112(2): 463-72.

Freeman AJ, Dore GJ, Law MG, Thorpe M, Von OJ, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34(4 Pt 1): 809-16.

Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86(7): 1143-50.

Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993; 118(2): 150-3.

Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6(3): 133-7.

Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32(3): 477-81.

Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23(6): 1334-40.

Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2(2): 165-73.

Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97(9): 2419-25.

Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997; 92(8): 1302-4.

Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33(1): 196-200.

Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques--a review. Gastrointest Endosc 1982; 28(2): 102-4.

Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113(5): 1609-16.

Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994; 39(11): 2426-32.

Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 37(8): 1379-83.

Zuckerman E, Lanir A, Sabo E, Rosenvald-Zuckerman T, Matter I, Yeshurun D, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94(6): 1613-8.

Collazos J. Clinical and laboratory evaluation of CA 19-9 in cirrhotic patients. Eur J Med 1992; 1(4): 215-8.

Kadayifci A, Simsek H, Savas MC, Toppare M. Serum tumor markers in chronic liver disease. Neoplasma 1996; 43(1): 17-21.

Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol 1988; 24(7): 1083-91.

Schoniger-Hekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 2006; 51(2): 338-45.

Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68(6): 1075-82.

Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68(5): 1331-7.

Bast RC, Jr., Klug TL, St JE, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309(15): 883-7.

Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50(6): 765-9.

Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14(5): 1545-51.

Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 2007; 8(9): 813-21.

Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M. Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res 2000; 20(2B): 1201-3.

Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 2000; 77(2): 254-7.

Sari R, Yildirim B, Sevinc A, Hilmioglu F. Re. Zuckerman et al.--Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am J Gastroenterol 2001; 96(1): 253-4.

Sevinc A, Buyukberber S, Sari R. Elevated serum CA-125 levels: hepatitis or ascites? Gynecol Oncol 2000; 76(1): 141-2.

Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003; 65(1): 1-6.

Ahmed AS, Long M, Donaldson D. Lessons to be learned: a case study approach: ascites and elevated serum CA 125 due to a pancreatic carcinoma. A diagnostic dilemma. J R Soc Promot Health 2000; 120(1): 47-51.

Sevinc A, Sari R, Camci C, Buyukberber S. A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement. J R Soc Promot Health 2000; 120(4): 268-70.

Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22(6): 696-9.

Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc 2002; 77(6): 538-41.

Collazos J, Genolla J, Ruibal A. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin Chim Acta 1992; 210(1-2): 145-51.

Pissaia A, Jr., Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc 2009; 41(2): 682-4.

Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, et al. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc 2009; 108(3): 210-8.

Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Alpha-fetoprotein serum concentration in different stages of liver cirrhosis. Rocz Akad Med Bialymst 1997; 42(1): 75-80.




Creative Commons Attribution-NonCommercial 4.0

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.